Clinical trials: Myeloma, Multiple
Breast Cancer, Hypercalcemia of Malignancy
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering…
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer
- Trial name
- NCT00896454
- Testing
- denosumab
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 33 people
- Sponsor
- Amgen
Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a…
- Trial name
- LIGHTHOUSE (NCT04649060)
- Testing
- Melflufen, Dexamethasone, Daratumumab
- Where
- 26 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 54 people
- Sponsor
- Oncopeptides AB
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
This randomized phase II trial studies how well ixazomib and dexamethasone or ixazomib, dexamethasone, and lenalidomide work based on the presence of the rearrangement of a gene called nuclear factor of kappa light polypeptide…
- Trial name
- NCT02765854
- Testing
- Dexamethasone, Ixazomib, Lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory Multiple Myeloma
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.
- Trial name
- NCT00478777
- Testing
- Lenalidomide, dexamethasone
- Where
- 48 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Celgene Corporation
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
This phase II trial is studying how well sunitinib works in treating patients with relapsed multiple myeloma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00514137
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. The initial patients on the dose-finding portion of this study will be enrolled through a single institution.
- Trial name
- NCT00536575
- Testing
- Bortezomib, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Relapsed or Refractory Multiple Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
- Trial name
- NCT03512353
- Testing
- Dexamethasone, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Multiple Myeloma
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma.
- Trial name
- FUSIONMM-003 (NCT02807454)
- Testing
- Daratumumab, Durvalumab, Pomalidomide
- Where
- 64 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Celgene
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ROS1 translocation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439253
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
This multicenter, open-label trial will randomize participants with multiple myeloma to a regimen of ibandronate or zoledronate in order to compare the incidence of nephrotoxicity, measured as creatinine clearance (CrCl)…
- Trial name
- COMPARE (NCT02739594)
- Testing
- Ibandronate, Zoledronate
- Where
- 56 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Kidney Cancer, Leukemia
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy, or that have become cancer.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00303719
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 342 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed [ND]…
- Trial name
- NCT02761187
- Testing
- No Intervention
- Where
- 137 sites in United States, Belgium and 13 more
- Volunteers
- 4,253 people
- Sponsor
- Takeda
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well trametinib and Akt inhibitor GSK2141795 work in treating patients with multiple myeloma that has come back (relapsed) or that does not respond to treatment (refractory).
- Trial name
- NCT01989598
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Trametinib
- Where
- 5 sites in Canada
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed…
- Trial name
- NCT04075721
- Testing
- M3258, M3258 20 mg
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapse/Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with…
- Trial name
- MARCH (NCT03944057)
- Testing
- ATG-010
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Antengene Corporation
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM)…
- Trial name
- NCT03567616
- Testing
- Venetoclax, Pomalidomide, Dexamethasone
- Where
- 11 sites in United States, Spain and 1 more
- Volunteers
- 8 people
- Sponsor
- AbbVie